The Novel TORC1/2 Kinase Inhibitor PQR620 Has Anti-Tumor Activity in Lymphomas as a Single Agent and in Combination with Venetoclax

The phosphatidylinositol 3-kinase (PI3K)/AKT/mammalian target of rapamycin (mTOR) signaling cascade is an important therapeutic target for lymphomas. Rapamycin-derivates as allosteric mTOR complex 1 (TORC1) inhibitors have shown moderate preclinical and clinical anti-lymphoma activity. Here, we asse...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cancers (Basel)
Main Authors: Tarantelli, Chiara, Gaudio, Eugenio, Hillmann, Petra, Spriano, Filippo, Sartori, Giulio, Aresu, Luca, Cascione, Luciano, Rageot, Denise, Kwee, Ivo, Beaufils, Florent, Zucca, Emanuele, Stathis, Anastasios, Wymann, Matthias P., Cmiljanovic, Vladimir, Fabbro, Doriano, Bertoni, Francesco
Formato: Artigo
Idioma:Inglês
Publicado em: MDPI 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6627883/
https://ncbi.nlm.nih.gov/pubmed/31167506
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11060775
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados